Last reviewed · How we verify
AMG 193
AMG 193 is a monoclonal antibody targeting PCSK9.
AMG 193 is a monoclonal antibody targeting PCSK9. Used for Hypercholesterolemia.
At a glance
| Generic name | AMG 193 |
|---|---|
| Also known as | MTA Cooperative PRMT5 inhibitor |
| Sponsor | Amgen |
| Drug class | PCSK9 inhibitor |
| Target | PCSK9 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
By binding to PCSK9, AMG 193 inhibits the degradation of LDL receptors, leading to increased LDL receptor expression on the liver surface and reduced circulating LDL cholesterol levels.
Approved indications
- Hypercholesterolemia
Common side effects
- Injection site reactions
- Musculoskeletal pain
Key clinical trials
- AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104). (PHASE1)
- A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103) (PHASE1)
- A Phase 2 Study of AMG 193 in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201) (PHASE2)
- A Study of AMG 193 in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) (PHASE1, PHASE2)
- A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AMG 193 CI brief — competitive landscape report
- AMG 193 updates RSS · CI watch RSS
- Amgen portfolio CI